Zealand Pharma A/S, a Danish biopharmaceutical company dedicated to the discovery and development of innovative peptide drugs, announces that its partner Sanofi has presented positive top-line results from the GetGoal-M Phase 3 study with lixisenatide (Lyxumia) for the treatment of Type 2 diabetes. Lixisenatide is an investigational once-daily GLP-1 agonist discovered by Zealand Pharma and licensed to Sanofi.
The results were presented in an oral presentation at the 21st World Diabetes Congress in Dubai, United Arab Emirates, and titled: “Efficacy and safety of lixisenatide QD 2) morning and evening injections versus placebo in T2DM inadequately controlled on metformin (GetGoal-M)”.
GetGoal-M is the seventh study under the global GetGoal Phase 3 program, and the eighth consecutive Phase 3 study including the GetGoal Duo 1 study, to report positive results that support the efficacy and safety of lixisenatide as a potential new treatment option for patients with Type 2 diabetes.
Commenting on today’s announcement, David Solomon, Chief Executive Officer and President of Zealand Pharma, said: “Eight consecutively positive Phase 3 studies have now been reported for lixisenatide providing a substantial body of clinical evidence for the potential of lixisenatide as a new treatment option for patients with Type 2 diabetes and their caregivers. Lixisenatide has been filed for registration in Europe and regulatory submission in the United States is expected in Q4 2012.”
Date: December 8, 2011
Source: Zealand Pharma A/S